Summary
Bristol Myers Squibb (BMY) reported its first quarter 2022 financial results, demonstrating solid performance driven by key products. The company's revenue saw an increase, largely attributed to the continued strength of its flagship drugs, particularly those in oncology and immunology. While the top line grew, investors should note the ongoing investments in research and development and potential impacts from product exclusivity challenges. The company's cash flow generation remains robust, providing flexibility for strategic investments and shareholder returns.
Financial Highlights
57 data pointsBeta
Financial Statements
Beta
| Revenue | $11.65B |
| Cost of Revenue | $2.47B |
| Gross Profit | $9.18B |
| R&D Expenses | $2.26B |
| SG&A Expenses | $1.83B |
| Operating Expenses | $9.96B |
| Interest Expense | $326.00M |
| Net Income | $1.28B |
| EPS (Basic) | $0.60 |
| EPS (Diluted) | $0.59 |
| Shares Outstanding (Basic) | 2.15B |
| Shares Outstanding (Diluted) | 2.16B |
Key Highlights
- 1Revenue growth driven by key products like Eliquis, Opdivo, and Revlimid.
- 2Continued significant investment in Research and Development to fuel future pipeline growth.
- 3Strong cash flow generation supporting operational needs and potential capital allocation strategies.
- 4Management commentary indicates confidence in near-term product performance and long-term strategy.
- 5Awareness of ongoing patent cliffs and the company's strategy to mitigate their impact through portfolio diversification and new product launches.